86.72
price up icon2.02%   1.91
 
loading
前日終値:
$84.81
開ける:
$84.95
24時間の取引高:
771.44K
Relative Volume:
0.45
時価総額:
$16.93B
収益:
$4.58B
当期純損益:
$870.87M
株価収益率:
19.71
EPS:
4.4
ネットキャッシュフロー:
$945.58M
1週間 パフォーマンス:
+2.81%
1か月 パフォーマンス:
+2.26%
6か月 パフォーマンス:
+42.06%
1年 パフォーマンス:
+27.13%
1日の値動き範囲:
Value
$84.90
$87.24
1週間の範囲:
Value
$81.09
$87.24
52週間の値動き範囲:
Value
$53.56
$87.99

Incyte Corp Stock (INCY) Company Profile

Name
名前
Incyte Corp
Name
セクター
Healthcare (1151)
Name
電話
(302) 498-6700
Name
住所
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
職員
2,617
Name
Twitter
@Incyte
Name
次回の収益日
2025-02-10
Name
最新のSEC提出書
Name
INCY's Discussions on Twitter

INCY を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
INCY
Incyte Corp
86.67 16.56B 4.58B 870.87M 945.58M 4.40
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
403.64 100.41B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.96 59.59B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.86 59.77B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
773.12 45.14B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
343.13 37.42B 3.81B -644.79M -669.77M -6.24

Incyte Corp Stock (INCY) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-08-06 アップグレード Wells Fargo Equal Weight → Overweight
2025-08-01 開始されました Barclays Overweight
2025-06-16 アップグレード Stifel Hold → Buy
2025-03-18 ダウングレード Guggenheim Buy → Neutral
2025-03-18 ダウングレード William Blair Outperform → Mkt Perform
2024-12-17 開始されました UBS Neutral
2024-10-29 アップグレード BofA Securities Neutral → Buy
2024-10-01 開始されました Wolfe Research Outperform
2024-09-18 ダウングレード Truist Buy → Hold
2024-07-02 ダウングレード BMO Capital Markets Market Perform → Underperform
2024-05-23 開始されました Deutsche Bank Hold
2024-04-23 開始されました Cantor Fitzgerald Neutral
2024-02-23 開始されました Jefferies Buy
2024-02-14 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2023-12-13 アップグレード Leerink Partners Market Perform → Outperform
2023-12-04 アップグレード Guggenheim Neutral → Buy
2023-11-21 ダウングレード Goldman Buy → Neutral
2023-07-25 開始されました Citigroup Buy
2023-05-04 ダウングレード BofA Securities Buy → Neutral
2023-04-10 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2023-03-24 アップグレード SVB Securities Underperform → Market Perform
2023-01-31 開始されました Piper Sandler Overweight
2022-08-03 ダウングレード Evercore ISI Outperform → In-line
2022-08-03 ダウングレード Guggenheim Buy → Neutral
2022-07-28 開始されました Wells Fargo Equal Weight
2022-02-09 ダウングレード SVB Leerink Mkt Perform → Underperform
2022-01-18 アップグレード RBC Capital Mkts Sector Perform → Outperform
2021-11-19 開始されました BMO Capital Markets Market Perform
2021-07-20 アップグレード The Benchmark Company Hold → Buy
2021-02-10 ダウングレード SVB Leerink Mkt Perform → Underperform
2021-01-07 開始されました Truist Buy
2021-01-04 アップグレード Guggenheim Neutral → Buy
2020-06-16 開始されました The Benchmark Company Hold
2020-05-06 ダウングレード JP Morgan Overweight → Neutral
2020-04-29 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-04-01 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-03-24 再開されました William Blair Outperform
2020-03-13 アップグレード BofA/Merrill Neutral → Buy
2020-02-04 再開されました BofA/Merrill Neutral
2020-01-03 繰り返されました BMO Capital Markets Market Perform
2020-01-03 ダウングレード Mizuho Buy → Neutral
2020-01-02 ダウングレード Guggenheim Buy → Neutral
2019-10-03 開始されました Mizuho Buy
2019-09-12 開始されました BMO Capital Markets Market Perform
2019-09-05 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2019-09-05 再開されました Morgan Stanley Equal-Weight
2019-09-05 アップグレード Oppenheimer Perform → Outperform
2019-05-21 開始されました Credit Suisse Neutral
2019-05-03 ダウングレード Barclays Overweight → Equal Weight
2019-04-11 開始されました Stifel Hold
2019-04-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2019-01-24 アップグレード William Blair Mkt Perform → Outperform
すべてを表示

Incyte Corp (INCY) 最新ニュース

pulisher
Sep 30, 2025

Poinciana Advisors Group LLC Makes New Investment in Incyte Corporation $INCY - MarketBeat

Sep 30, 2025
pulisher
Sep 29, 2025

Is Incyte Corporation stock a safe buy before earnings2025 Trade Ideas & Smart Swing Trading Techniques - newser.com

Sep 29, 2025
pulisher
Sep 28, 2025

Patton Albertson Miller Group LLC Acquires 5,497 Shares of Incyte Corporation $INCY - MarketBeat

Sep 28, 2025
pulisher
Sep 28, 2025

Patton Fund Management Inc. Takes $254,000 Position in Incyte Corporation $INCY - MarketBeat

Sep 28, 2025
pulisher
Sep 28, 2025

China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication - GlobeNewswire Inc.

Sep 28, 2025
pulisher
Sep 27, 2025

Candlestick signals on Incyte Corporation stock todayMarket Performance Recap & Breakout Confirmation Alerts - newser.com

Sep 27, 2025
pulisher
Sep 27, 2025

Will Incyte Corporation stock outperform value stocks2025 EndofYear Setup & Technical Confirmation Alerts - newser.com

Sep 27, 2025
pulisher
Sep 27, 2025

Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple Conditions - Yahoo Finance

Sep 27, 2025
pulisher
Sep 25, 2025

INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - MSN

Sep 25, 2025
pulisher
Sep 25, 2025

How to use Fibonacci retracement on Incyte CorporationJuly 2025 Weekly Recap & Accurate Buy Signal Notifications - newser.com

Sep 25, 2025
pulisher
Sep 25, 2025

Jim Cramer Calls Incyte “Way Too Cheap” - Yahoo Finance

Sep 25, 2025
pulisher
Sep 25, 2025

Ruffer LLP Sells 9,988 Shares of Incyte Corporation $INCY - MarketBeat

Sep 25, 2025
pulisher
Sep 24, 2025

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 24, 2025 - biospace.com

Sep 24, 2025
pulisher
Sep 24, 2025

RBC Capital Raises Price Target for Incyte (INCY) to USD 81 | IN - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Incyte stock price target raised to $81 from $72 at RBC Capital - Investing.com

Sep 24, 2025
pulisher
Sep 24, 2025

Guggenheim Reaffirms "Neutral" Rating for Incyte (NASDAQ:INCY) - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Incyte’s Povorcitinib Shows Sustained Efficacy in Phase 3 HS Trial, Supports 2025/2026 Regulatory Submissions - Insider Monkey

Sep 24, 2025
pulisher
Sep 23, 2025

Mn Services Vermogensbeheer B.V. Sells 6,600 Shares of Incyte Corporation $INCY - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Is Incyte Stock Outperforming The S&P 500? - Barchart.com

Sep 23, 2025
pulisher
Sep 23, 2025

Incyte Corporation (NASDAQ:INCY) Short Interest Down 21.8% in August - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Incyte Corporation $INCY Stake Lowered by Diversified Trust Co - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer - BioSpace

Sep 23, 2025
pulisher
Sep 23, 2025

NorthCrest Asset Manangement LLC Has $777,000 Stock Holdings in Incyte Corporation $INCY - MarketBeat

Sep 23, 2025
pulisher
Sep 22, 2025

Sovran Advisors LLC Sells 12,174 Shares of Incyte Corporation $INCY - MarketBeat

Sep 22, 2025
pulisher
Sep 22, 2025

Is Incyte Corporation a candidate for recovery playJuly 2025 Levels & Proven Capital Preservation Tips - newser.com

Sep 22, 2025
pulisher
Sep 22, 2025

Incyte (NASDAQ:INCY) Price Target Raised to $115.00 at Stifel Nicolaus - MarketBeat

Sep 22, 2025
pulisher
Sep 22, 2025

Stifel Raises Price Target for Incyte (INCY) to $115 While Maint - GuruFocus

Sep 22, 2025
pulisher
Sep 22, 2025

Incyte appoints Dave Gardner as new chief strategy officer - Investing.com

Sep 22, 2025
pulisher
Sep 22, 2025

Stifel Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $115 - 富途牛牛

Sep 22, 2025
pulisher
Sep 22, 2025

Incyte’s SWOT analysis: stock outlook mixed amid pipeline progress, jakafi concerns - Investing.com

Sep 22, 2025
pulisher
Sep 22, 2025

Incyte stock price target raised to $115 by Stifel on pediatric approval - Investing.com

Sep 22, 2025
pulisher
Sep 21, 2025

Incyte (NASDAQ:INCY) EVP Sells $23,115.70 in Stock - MarketBeat

Sep 21, 2025
pulisher
Sep 21, 2025

Pallas Capital Advisors LLC Reduces Holdings in Incyte Corporation $INCY - MarketBeat

Sep 21, 2025
pulisher
Sep 21, 2025

Perpetual Ltd Purchases New Holdings in Incyte Corporation $INCY - MarketBeat

Sep 21, 2025
pulisher
Sep 20, 2025

34,082 Shares in Incyte Corporation $INCY Acquired by Strs Ohio - MarketBeat

Sep 20, 2025
pulisher
Sep 20, 2025

How Investors May Respond To Incyte (INCY) Expanding Opzelura’s Pediatric Use Following FDA Approval - Yahoo Finance

Sep 20, 2025
pulisher
Sep 20, 2025

Swedbank AB Raises Stock Holdings in Incyte Corporation $INCY - MarketBeat

Sep 20, 2025
pulisher
Sep 20, 2025

Baader Bank Aktiengesellschaft Invests $424,000 in Incyte Corporation $INCY - MarketBeat

Sep 20, 2025
pulisher
Sep 20, 2025

4,558 Shares in Incyte Corporation $INCY Purchased by OMNI 360 Wealth Inc. - MarketBeat

Sep 20, 2025
pulisher
Sep 20, 2025

Incyte Corporation (NASDAQ:INCY) Given Average Rating of "Hold" by Brokerages - MarketBeat

Sep 20, 2025
pulisher
Sep 19, 2025

Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink? - MSN

Sep 19, 2025
pulisher
Sep 19, 2025

Guggenheim Reiterates Neutral Rating for Incyte (INCY) | INCY Stock News - GuruFocus

Sep 19, 2025
pulisher
Sep 19, 2025

INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - Yahoo Finance

Sep 19, 2025
pulisher
Sep 19, 2025

FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In ChildrenIncyte (NASDAQ:INCY) - Benzinga

Sep 19, 2025
pulisher
Sep 19, 2025

Incyte (NASDAQ:INCY) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat

Sep 19, 2025
pulisher
Sep 19, 2025

Invst LLC Makes New $315,000 Investment in Incyte Corporation $INCY - MarketBeat

Sep 19, 2025
pulisher
Sep 19, 2025

CEO Change: Is Incyte Corporation showing insider buyingMarket Activity Summary & Advanced Technical Signal Analysis - خودرو بانک

Sep 19, 2025
pulisher
Sep 18, 2025

Loss Report: What is the next catalyst for Incyte CorporationJuly 2025 Decliners & Target Return Focused Stock Picks - خودرو بانک

Sep 18, 2025
pulisher
Sep 18, 2025

FDA approves Opzelura for atopic dermatitis in children ages 2 and up - Investing.com

Sep 18, 2025
pulisher
Sep 18, 2025

US FDA approves Incyte's eczema cream for pediatric patients - Reuters

Sep 18, 2025
pulisher
Sep 18, 2025

FDA Greenlights Incyte's Opzelura Cream for Pediatric Dermatitis Treatment - GuruFocus

Sep 18, 2025

Incyte Corp (INCY) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$36.30
price up icon 2.76%
$31.72
price up icon 3.39%
$101.83
price up icon 3.29%
$147.52
price up icon 2.61%
biotechnology ONC
$343.50
price up icon 0.82%
大文字化:     |  ボリューム (24 時間):